According to research reviewed by Gram, a 2026 study in mice found that navitoclax, a drug that removes worn-out liver cells, eased fatty buildup and scarring in a fatty liver disease model when delivered in tiny engineered packages. The packaging was designed to lower the risk of side effects, and human trials have not been done yet.
Fatty liver disease, now called MASH, causes fat buildup, inflammation, and scarring in the liver. Researchers have found that some liver cells stop dividing and linger in a damaged state called senescence, which may fuel the disease. According to research reviewed by Gram, scientists tested navitoclax, a drug that removes these worn-out cells, and found it reduced harmful changes in lab dishes. However, the drug can be toxic at higher doses. To reduce this risk, the team wrapped navitoclax in tiny packages made from cell membranes and synthetic fats. In a mouse model of the disease, fed a Western-style diet high in fat and fructose, these packages reduced liver fat, lowered a disease activity score, and eased scarring. The treatment did not lower platelet counts or hemoglobin at the dose tested. The work is early, and studies in people are still needed.
Key Statistics
A 2026 study published in the Journal of Controlled Release found that navitoclax packaged in engineered cell-derived vesicles reduced liver fat and scarring in a mouse model of fatty liver disease.
In the same 2026 mouse study, the packaged drug did not lower platelet counts or hemoglobin levels at the dose tested, which addresses a known side effect of navitoclax.
The Quick Take
- What they studied: Whether removing aging liver cells with a drug, delivered in a safer way, could help treat fatty liver disease.
- Who participated: No people took part. The work used lab-grown liver, fat, and immune cells, plus mice fed a high-fat, high-sugar diet with fructose. The number of animals was not reported in the summary.
- Key finding: The drug wrapped in lab-made packages reduced liver fat and scarring in the mice without lowering platelet counts or hemoglobin at the dose tested. The summary does not give exact percentages, so the size of the effect is not yet clear.
- What it means for you: This is early laboratory and animal research, so it does not mean you should change any treatment. Proven steps for fatty liver disease, such as cutting back on added sugar and losing excess weight, remain the best approach. Talk with a doctor about any concerns.
The Research Details
The researchers built several lab models to copy what happens inside a fatty liver. They grew liver cells and immune cells together and pushed the liver cells into the aging state called senescence. This let them watch how fat builds up and how inflammation spreads between the two cell types.
Next, they tested three approaches on these cells: a natural fluid-filled particle taken from fat cells, the drug navitoclax, and a new delivery system. The delivery system used tiny packages made from liver cell membranes mixed with synthetic fats. The packages were designed to carry navitoclax in a more controlled way.
Finally, the team tested the packaged drug in mice fed a Western-style diet with fructose, which causes fatty liver disease in animals. They then compared liver fat, disease activity scores, scarring, and blood counts across treatment groups.
Lab dishes allow scientists to test one factor at a time, such as aging cells or a specific drug, without the many other changes that happen in a living body. Mouse models then show whether a treatment works in a whole animal, which is a necessary step before testing in people. Together, these steps help separate promising ideas from ones that fail early.
The study was published in a respected journal focused on drug delivery, and it used several complementary methods, which strengthens confidence in the results. However, the summary does not report how many mice or cells were used, how results were measured in detail, or how long treatment lasted. Animal and lab findings often do not carry over to people, so these results should be viewed as a starting point rather than proof.
What the Results Show
The researchers found that liver cells in the aging state stored more fat and sent out stronger inflammatory signals to immune cells. This supports the idea that these cells play a role in driving fatty liver disease. When the team treated these cells, the fluid-filled particles from fat cells reduced some signs of aging, but their effects varied depending on the situation. This made them harder to control.
Navitoclax reduced the signs of aging in lab cells, but the drug can be toxic at higher doses, which limits its use in people. The new packaging system kept the drug’s ability to clear aging cells while also lowering inflammation and signs of scarring in the lab. This suggests the packaging may help the drug work with fewer risks.
In mice with the fatty liver disease model, the packaged navitoclax reduced fat in the liver, lowered the disease activity score, and eased scarring. These changes point to a real effect on the disease in a living animal. The researchers also noted that the treatment did not reduce platelet counts or hemoglobin at the dose tested. Both are blood measures that can drop with navitoclax, so this is an encouraging safety signal, though only for that dose.
The team reported that the packaged drug kept its ability to remove aging cells, which matters because many drug-delivery systems lose their strength during packaging. The fact that the packaging did not cause blood count drops at the tested dose is also important, since blood cell loss is one of the main limits of navitoclax. These results suggest that controlled delivery may make powerful drugs safer to explore, though more dose testing is needed.
Drugs that remove aging cells, called senolytics, have been studied in several age-related conditions in earlier work. The authors note that their use in fatty liver disease has been studied far less. This study adds to that small body of work by showing a specific drug, delivered in a new way, can ease liver damage in an animal model. It builds on the idea that aging cells help push the disease forward.
The biggest limitation is that the study was done in lab cells and mice, not in people. Mouse results often do not match human outcomes, and a treatment that works in animals can fail in clinical trials. The summary also does not report sample sizes, exact effect sizes, treatment length, or long-term safety. Only one dose of the drug was tested for blood effects, so safety at other doses is unknown. Human trials would be needed to learn whether the approach helps patients.
The Bottom Line
Based on this early work, the strongest takeaway is that aging liver cells may be a useful target for future fatty liver treatments. Confidence in the drug-delivery approach is low to moderate because it has only been tested in cells and mice. Confidence that people should change treatment now is none, since no human evidence exists yet. The best-supported steps remain healthy eating, regular physical activity, and weight management under medical guidance.
People with fatty liver disease or MASH, their doctors, and researchers working on liver disease may find this study useful. People who are healthy and have no liver concerns do not need to act on these findings. Anyone already taking medicine for liver disease should keep following their doctor’s plan rather than seeking this experimental drug.
Drugs usually take many years to move from early lab and animal studies to human trials and then to approval. Even if later studies succeed, a new treatment like this could take a decade or more to reach patients. Anyone with fatty liver disease should expect current care to stay the same for the foreseeable future.
Frequently Asked Questions
Can a drug that removes aging liver cells treat fatty liver disease?
Early research suggests it may help. A 2026 mouse study found that navitoclax, a drug that removes aging cells, reduced liver fat and scarring when delivered in engineered packages. Human testing has not yet been done, so the approach is not available as a treatment.
What is MASH and how is it different from regular fatty liver?
MASH, or metabolic dysfunction-associated steatohepatitis, is a serious form of fatty liver disease. It involves fat buildup, inflammation, and progressive scarring in the liver. Lifestyle changes such as eating less added sugar and losing excess weight remain the main proven steps for managing it.
Why does navitoclax need special packaging?
Navitoclax can cause dose-dependent toxicity, which limits how much of it can be safely used. In the study, packaging the drug in cell-derived membranes with synthetic fats kept its ability to clear aging cells. The packaged version also did not lower platelet counts or hemoglobin at the tested dose.
Should I change my diet based on this senolytic liver research?
Current evidence does not require a diet change based on this study alone. Established advice for fatty liver disease includes limiting added sugar, eating more vegetables and whole foods, staying physically active, and maintaining a healthy weight. Discuss personal changes with a doctor.
Want to Apply This Research?
- Track weekly added sugar intake in grams and weekly minutes of moderate activity, such as brisk walking. Also log weight once a week at the same time of day. These measures are easy to record and link directly to fatty liver risk.
- Set a simple goal to swap one sugary drink per day for water or unsweetened tea, and log it in the app. Add a daily 20-minute walk and check off each day. Small, repeatable changes are easier to keep than large, sudden ones.
- Review trends monthly rather than daily, looking for steady changes in weight, activity, and sugar intake. Share these trends with a doctor at regular checkups, since they can order liver tests such as blood work or imaging. Update the app’s goals as advice from a healthcare provider changes.
This article summarizes early laboratory and mouse research published in a scientific journal. The findings have not been tested in people and should not be used to make medical decisions. Anyone with fatty liver disease, MASH, or other liver concerns should consult a qualified healthcare provider before changing diet, exercise, or medications.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.